Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Long-Term Deferred Tax (2021 - 2025)

Nutex Health's Long-Term Deferred Tax history spans 4 years, with the latest figure at $12.9 million for Q2 2025.

  • For Q2 2025, Long-Term Deferred Tax changed N/A year-over-year to $12.9 million; the TTM value through Jun 2025 reached $12.9 million, changed N/A, while the annual FY2024 figure was $8.0 million, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q2 2025 was $12.9 million at Nutex Health, up from $10.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $12.9 million in Q2 2025 and bottomed at $2.4 million in Q3 2022.
  • The 4-year median for Long-Term Deferred Tax is $2.4 million (2021), against an average of $5.0 million.
  • The largest YoY upside for Long-Term Deferred Tax was 1.21% in 2022 against a maximum downside of 38.53% in 2022.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $3.9 million in 2021, then crashed by 38.53% to $2.4 million in 2022, then skyrocketed by 232.79% to $8.0 million in 2024, then surged by 60.91% to $12.9 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Long-Term Deferred Tax are $12.9 million (Q2 2025), $10.5 million (Q1 2025), and $8.0 million (Q4 2024).